Indeed, in a grafted tumor model, CCR2 inhibition was effective at reducing TAMs (20, 34), which is consistent with our finding here in autochthonous primary and metastatic disease that TAM reductions render PDA susceptible to ICB. Here, CCR2 is linked to Patent ductus arteriosus.